0.92
-7.99%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About OS Therapies
From its filings with the US Securities and Exchange Commission
OS Therapies is based in Rockville, Maryland and is incorporated in Delaware. Its shares trade on NYSE under the ticker OSTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $28.8m. At that date it held total assets of $6.8m and shareholders' equity of −$6.1m.
Medicines Agency (EMA) regarding the clinical and biomarker data for OST-HER2 in recurrent, fully resected pulmonary metastatic Osteosarcoma.
Control, and 24-month overall survival of 61% compared to 40%, respectively. Survival assessments were conducted at three-month intervals.
We may consider out-licensing OST-HER2 to animal health companies for veterinary use in dogs diagnosed with Osteosarcoma, one year of age or older, consistent with prior conditional licensure and preclinical data.
Obtain marketing approval for OST-HER2 in Osteosarcoma, then quickly pivot to a master protocol within breast, esophageal, lung and other solid tumors where metastases express HER2 that could be targeted by immune cells.
Complete pre-clinical and toxicology trials with the lead drug candidate for OST-tADC (OST-tADC-A, Exatecan-silanol-FRa) and submit an IND to initiate a Phase I trial in ovarian cancer and other folate receptor alpha-overexpressing tumors, including endometrial cancer and certain Osteosarcomas. We believe that positive results from preclinical and GLP toxicology studies may also facilitate potential out-licensing opportunities for SiLinker and CAPs drug products, without limiting therapeutic development.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Aug 2024
- Employees
- 4
- Website
- ostherapies.com ↗
- Head office
- 15825 SHADY GROVE ROAD, ROCKVILLE, MD, 20850
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Paul RomnessChairman of the Board, President, Chief Executive Officer, Founder, since 2018$3.4m
- Mr. Christopher AcevedoChief Financial Officer$158,523
- Dr. Robert PetitChief Medical Officer, Chief Scientific Officer$665,046
- Mr. Gerald CommissiongChief Business Officer
- Mr. Karim GalzahrDirector
- Mr. John CiccioIndependent Director$24,505
- Mr. Olivier JarryIndependent Director$24,505
- Ms. Avril Mckean DieserIndependent Director$24,505
- Dr. Theodore SearchIndependent Director$24,505
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- OS Therapies Inc has a focused pipeline targeting Osteosarcoma and solid tumors with two drug technologies.
- OST-HER2 uses a modified Listeria strain for immunotherapy against HER2 peptides.
- OST-tADC features tunable pH sensitive silicone linkers for targeted cancer treatments.
Weaknesses
- The company employs only four full-time staff members as of 2024.
- OS Therapies Inc went public on 1 August 2024 with limited operational history.
- The company's clinical-stage status indicates early development phase for its products.
Opportunities
- The growing biotechnology sector in the US offers expansion potential for OS Therapies Inc.
- Osteosarcoma treatment market shows unmet needs for new therapies.
- Solid tumor treatments represent a significant market opportunity in oncology.
Threats
- Competition in the biotechnology sector for cancer treatments is intense.
- Regulatory approval processes for new cancer therapies can be lengthy.
- The biotechnology industry faces high development costs and financial risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.